ReviewFrontiers in cellular and infection microbiology2023
Antibiotic adjuvants: synergistic tool to combat multi-drug resistant pathogens.
Review in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Efficacy of Cold Atmospheric Plasma Against Methicillin-Resistant Staphylococcus aureus Biofilms: A Systematic Review of In Vitro Studies.BioMed research international · 2026Pooled it
- Dual- vs. Single-Antibiotic Loaded Cement for Hip Hemiarthroplasty: A Systematic Review and Meta-Analysis.Orthopaedic surgery · 2025Pooled it
- Differential modulation of gentamicin antibacterial activity by vitamin B12 and vitamin D3 against Gram-positive and Gram-negative bacteria: anAnnals of medicine · 2026Article
- Efflux modulation as an antimicrobial strategy: mechanisms and translational perspectives.npj drug discovery · 2026Review
- Small-molecule inhibitors block NorA efflux by conformational trapping.Nature chemical biology · 2026Article
- Effective Abatement of Multidrug-resistant Pathogens Employing Natural Polyphenols and Polyphenol-based Formulations: A Systematic Review and Integrated Network Pharmacology Approach.Applied biochemistry and biotechnology · 2026Review
- Metabolic adaptations in antibiotic-resistantMicrobiology spectrum · 2026Article
- Deciphering microbial biofilm: mechanism, infection, and advanced approaches for control.Folia microbiologica · 2026Review
- Antimicrobial Peptides as Antibiotic Adjuvants: Overcoming Resistance through Multifaceted Mechanisms.Probiotics and antimicrobial proteins · 2026Article
- Host-Pathogen Dual Targeting With Repurposed Drugs Identifies a Synergistic Therapy for Intracellular Staphylococcus aureus.MicrobiologyOpen · 2026Article
- Marine microorganisms as probiotics in the aquaculture of sea cucumber (Apostichopus japonicus).Antonie van Leeuwenhoek · 2026Review
- Synergistic Potential of Repurposing non-β-lactam Compounds as Class A serine β-lactamases Inhibitor: Insights from MolecularDocking, Molecular Dynamics Simulations and Antimicrobial Potentiation.Scientific reports · 2026Article
- Repurposing flufenamic acid as a putative PmrB-directed adjuvant to restore colistin activity inMicrobiology spectrum · 2026Article
- Characterization of the YCjN ABC Transporter in Escherichia coli: Role in Maltose and Ethidium Bromide Transport.Molecular biotechnology · 2026Article
- Mechanisms of Bacterial Resistance and Innovative Strategies to Overcome Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Reclaiming the Microbial Battlefield: Adjuvant Strategies to Overcome Antibiotic Resistance.Microorganisms · 2026Review
- Ecological partitioning enables phage-antibiotic cooperation in a human Pseudomonas infection.Nature communications · 2026Article
- Berberine Interferes with the Molecular Landscape of Biofilm-Driven Pathogenicity.Pathogens (Basel, Switzerland) · 2026Review
- Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics.MicrobiologyOpen · 2026Review
- Fatty Acids as Prebiotics and Their Role in Antibiofilm Activity.Antibiotics (Basel, Switzerland) · 2026Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of multi-drug resistant (MDR) pathogens poses a significant challenge to the field of infectious disease treatment. To overcome this problem, novel strategies are being explored to enhance the effectiveness of antibiotics. Antibiotic adjuvants have emerged as a promising approach to combat MDR pathogens by acting synergistically with antibiotics. This review focuses on the role of antibiotic adjuvants as a synergistic tool in the fight against MDR pathogens. Adjuvants refer to compounds or agents that enhance the activity of antibiotics, either by potentiating their effects or by targeting the mechanisms of antibiotic resistance. The utilization of antibiotic adjuvants offers several advantages. Firstly, they can restore the effectiveness of existing antibiotics against resistant strains. Adjuvants can inhibit the mechanisms that confer resistance, making the pathogens susceptible to the action of antibiotics. Secondly, adjuvants can enhance the activity of antibiotics by improving their penetration into bacterial cells, increasing their stability, or inhibiting efflux pumps that expel antibiotics from bacterial cells. Various types of antibiotic adjuvants have been investigated, including efflux pump inhibitors, resistance-modifying agents, and compounds that disrupt bacterial biofilms. These adjuvants can act synergistically with antibiotics, resulting in increased antibacterial activity and overcoming resistance mechanisms. In conclusion, antibiotic adjuvants have the potential to revolutionize the treatment of MDR pathogens. By enhancing the efficacy of antibiotics, adjuvants offer a promising strategy to combat the growing threat of antibiotic resistance. Further research and development in this field are crucial to harness the full potential of antibiotic adjuvants and bring them closer to clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.